2021
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
BLANCHETTE, V. S., L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO et. al.Základní údaje
Originální název
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
Autoři
BLANCHETTE, V. S. (garant), L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO, J. CURTIN, S. JACKSON, L. KHOO, Vladimir KOMRSKA (203 Česká republika), D. LILLICRAP, M. MORFINI, Gabriela ROMANOVÁ (203 Česká republika, domácí), D. STEPHENS, Ester ZAPOTOCKA (203 Česká republika), M. L. RAND a Jan BLATNÝ (203 Česká republika, domácí)
Vydání
THROMBOSIS AND HAEMOSTASIS, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0340-6245
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 6.681
Kód RIV
RIV/00216224:14110/21:00121731
Organizační jednotka
Lékařská fakulta
UT WoS
000640018700001
Klíčová slova anglicky
factor VIII; hemophilia A; pharmacokinetic; observational study; population PK
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 25. 2. 2022 10:56, Mgr. Tereza Miškechová
Anotace
V originále
Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C]<2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24hours post home infusion of FVIII and then 3hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.